GRM2 and schizophrenia: The first drug targeting mGluR2/3 receptors that has been clinically tested in human for the treatment of schizophrenia was LY-2140023, as it was suspected that it might normalize hyperactive cortical pyramidal neurons in the thalamus, prefrontal cortex and limbic system [102].